Compare GKOS & MTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | MTH |
|---|---|---|
| Founded | 1998 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.1B |
| IPO Year | 2015 | 1988 |
| Metric | GKOS | MTH |
|---|---|---|
| Price | $107.89 | $74.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $122.08 | $82.88 |
| AVG Volume (30 Days) | ★ 1.1M | 862.9K |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 2.30% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.50 |
| Revenue | $469,820,000.00 | ★ $6,043,594,000.00 |
| Revenue This Year | $30.89 | N/A |
| Revenue Next Year | $24.36 | $5.61 |
| P/E Ratio | ★ N/A | $9.96 |
| Revenue Growth | ★ 30.38 | N/A |
| 52 Week Low | $73.16 | $59.27 |
| 52 Week High | $163.71 | $96.08 |
| Indicator | GKOS | MTH |
|---|---|---|
| Relative Strength Index (RSI) | 73.56 | 66.68 |
| Support Level | $104.11 | $72.05 |
| Resistance Level | $107.18 | $74.84 |
| Average True Range (ATR) | 4.40 | 2.10 |
| MACD | 1.26 | 0.94 |
| Stochastic Oscillator | 92.97 | 95.51 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.